Partner Content Partner Content Peripheral Interventions Market will achieve 8.7% CAGR up to... Peripheral Intervention Industry to hit $10.5bn by 2025
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
